Name | Value |
---|---|
Revenues | 198.8M |
Cost of Revenue | 45.2M |
Gross Profit | 153.5M |
Operating Expense | 61.7M |
Operating I/L | 91.9M |
Other Income/Expense | -15.1M |
Interest Income | 80.0M |
Pretax | 76.8M |
Income Tax Expense | 11.6M |
Net Income/Loss | 65.2M |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for autoimmune, eye, and bone disorders, as well as cancer. Its lead programs include biosimilars to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, age-related macular degeneration, macular edema, diabetic retinopathy, and to prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in cancer patients. The company also offers biosimilars for other inflammatory conditions, immunology, and oncology products.